Citius Pharmaceuticals, Inc.
Citius Pharmaceuticals, Inc. (CTXR) Stock Competitors & Peer Comparison
See (CTXR) competitors and their performances in Stock Market.
Peer Comparison Table: Biotechnology Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| CTXR | $0.88 | -8.48% | 9.8M | -0.36 | -$2.46 | N/A |
| VRTX | $466.10 | -0.69% | 118.4B | 30.46 | $15.30 | N/A |
| REGN | $756.91 | +1.49% | 78.6B | 18.26 | $41.46 | +0.48% |
| VRNA | $106.91 | +0.11% | 72.7B | -102.80 | -$1.04 | N/A |
| ARGX | $703.30 | +0.41% | 43.5B | 35.88 | $19.60 | N/A |
| SGEN | $228.74 | -0.07% | 43.2B | -57.19 | -$4.00 | N/A |
| ALNY | $318.91 | +1.75% | 42.3B | 137.46 | $2.32 | N/A |
| INSM | $144.60 | +3.66% | 31.2B | -22.52 | -$6.42 | N/A |
| UTHR | $534.30 | -0.34% | 23.4B | 19.16 | $27.88 | N/A |
| BNTX | $90.54 | -0.71% | 22.7B | -32.80 | -$2.76 | N/A |
Stock Comparison
CTXR vs VRTX Comparison March 2026
CTXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CTXR stands at 9.8M. In comparison, VRTX has a market cap of 118.4B. Regarding current trading prices, CTXR is priced at $0.88, while VRTX trades at $466.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CTXR currently has a P/E ratio of -0.36, whereas VRTX's P/E ratio is 30.46. In terms of profitability, CTXR's ROE is -0.53%, compared to VRTX's ROE of +0.23%. Regarding short-term risk, CTXR is more volatile compared to VRTX. This indicates potentially higher risk in terms of short-term price fluctuations for CTXR.Check VRTX's competition here
CTXR vs REGN Comparison March 2026
CTXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CTXR stands at 9.8M. In comparison, REGN has a market cap of 78.6B. Regarding current trading prices, CTXR is priced at $0.88, while REGN trades at $756.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CTXR currently has a P/E ratio of -0.36, whereas REGN's P/E ratio is 18.26. In terms of profitability, CTXR's ROE is -0.53%, compared to REGN's ROE of +0.15%. Regarding short-term risk, CTXR is more volatile compared to REGN. This indicates potentially higher risk in terms of short-term price fluctuations for CTXR.Check REGN's competition here
CTXR vs VRNA Comparison March 2026
CTXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CTXR stands at 9.8M. In comparison, VRNA has a market cap of 72.7B. Regarding current trading prices, CTXR is priced at $0.88, while VRNA trades at $106.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CTXR currently has a P/E ratio of -0.36, whereas VRNA's P/E ratio is -102.80. In terms of profitability, CTXR's ROE is -0.53%, compared to VRNA's ROE of -0.30%. Regarding short-term risk, CTXR is more volatile compared to VRNA. This indicates potentially higher risk in terms of short-term price fluctuations for CTXR.Check VRNA's competition here
CTXR vs ARGX Comparison March 2026
CTXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CTXR stands at 9.8M. In comparison, ARGX has a market cap of 43.5B. Regarding current trading prices, CTXR is priced at $0.88, while ARGX trades at $703.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CTXR currently has a P/E ratio of -0.36, whereas ARGX's P/E ratio is 35.88. In terms of profitability, CTXR's ROE is -0.53%, compared to ARGX's ROE of +0.34%. Regarding short-term risk, CTXR is more volatile compared to ARGX. This indicates potentially higher risk in terms of short-term price fluctuations for CTXR.Check ARGX's competition here
CTXR vs SGEN Comparison March 2026
CTXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CTXR stands at 9.8M. In comparison, SGEN has a market cap of 43.2B. Regarding current trading prices, CTXR is priced at $0.88, while SGEN trades at $228.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CTXR currently has a P/E ratio of -0.36, whereas SGEN's P/E ratio is -57.19. In terms of profitability, CTXR's ROE is -0.53%, compared to SGEN's ROE of -0.21%. Regarding short-term risk, CTXR is more volatile compared to SGEN. This indicates potentially higher risk in terms of short-term price fluctuations for CTXR.Check SGEN's competition here
CTXR vs ALNY Comparison March 2026
CTXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CTXR stands at 9.8M. In comparison, ALNY has a market cap of 42.3B. Regarding current trading prices, CTXR is priced at $0.88, while ALNY trades at $318.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CTXR currently has a P/E ratio of -0.36, whereas ALNY's P/E ratio is 137.46. In terms of profitability, CTXR's ROE is -0.53%, compared to ALNY's ROE of +0.90%. Regarding short-term risk, CTXR is more volatile compared to ALNY. This indicates potentially higher risk in terms of short-term price fluctuations for CTXR.Check ALNY's competition here
CTXR vs INSM Comparison March 2026
CTXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CTXR stands at 9.8M. In comparison, INSM has a market cap of 31.2B. Regarding current trading prices, CTXR is priced at $0.88, while INSM trades at $144.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CTXR currently has a P/E ratio of -0.36, whereas INSM's P/E ratio is -22.52. In terms of profitability, CTXR's ROE is -0.53%, compared to INSM's ROE of -1.68%. Regarding short-term risk, CTXR is more volatile compared to INSM. This indicates potentially higher risk in terms of short-term price fluctuations for CTXR.Check INSM's competition here
CTXR vs UTHR Comparison March 2026
CTXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CTXR stands at 9.8M. In comparison, UTHR has a market cap of 23.4B. Regarding current trading prices, CTXR is priced at $0.88, while UTHR trades at $534.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CTXR currently has a P/E ratio of -0.36, whereas UTHR's P/E ratio is 19.16. In terms of profitability, CTXR's ROE is -0.53%, compared to UTHR's ROE of +0.19%. Regarding short-term risk, CTXR is more volatile compared to UTHR. This indicates potentially higher risk in terms of short-term price fluctuations for CTXR.Check UTHR's competition here
CTXR vs BNTX Comparison March 2026
CTXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CTXR stands at 9.8M. In comparison, BNTX has a market cap of 22.7B. Regarding current trading prices, CTXR is priced at $0.88, while BNTX trades at $90.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CTXR currently has a P/E ratio of -0.36, whereas BNTX's P/E ratio is -32.80. In terms of profitability, CTXR's ROE is -0.53%, compared to BNTX's ROE of -0.06%. Regarding short-term risk, CTXR is more volatile compared to BNTX. This indicates potentially higher risk in terms of short-term price fluctuations for CTXR.Check BNTX's competition here
CTXR vs MRNA Comparison March 2026
CTXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CTXR stands at 9.8M. In comparison, MRNA has a market cap of 21.1B. Regarding current trading prices, CTXR is priced at $0.88, while MRNA trades at $53.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CTXR currently has a P/E ratio of -0.36, whereas MRNA's P/E ratio is -7.34. In terms of profitability, CTXR's ROE is -0.53%, compared to MRNA's ROE of -0.30%. Regarding short-term risk, CTXR is more volatile compared to MRNA. This indicates potentially higher risk in terms of short-term price fluctuations for CTXR.Check MRNA's competition here
CTXR vs ROIV Comparison March 2026
CTXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CTXR stands at 9.8M. In comparison, ROIV has a market cap of 20.2B. Regarding current trading prices, CTXR is priced at $0.88, while ROIV trades at $28.28.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CTXR currently has a P/E ratio of -0.36, whereas ROIV's P/E ratio is -24.17. In terms of profitability, CTXR's ROE is -0.53%, compared to ROIV's ROE of -0.18%. Regarding short-term risk, CTXR is more volatile compared to ROIV. This indicates potentially higher risk in terms of short-term price fluctuations for CTXR.Check ROIV's competition here
CTXR vs BGNE Comparison March 2026
CTXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CTXR stands at 9.8M. In comparison, BGNE has a market cap of 20.2B. Regarding current trading prices, CTXR is priced at $0.88, while BGNE trades at $184.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CTXR currently has a P/E ratio of -0.36, whereas BGNE's P/E ratio is -22.55. In terms of profitability, CTXR's ROE is -0.53%, compared to BGNE's ROE of +0.07%. Regarding short-term risk, CTXR is more volatile compared to BGNE. This indicates potentially higher risk in terms of short-term price fluctuations for CTXR.Check BGNE's competition here
CTXR vs RPRX Comparison March 2026
CTXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CTXR stands at 9.8M. In comparison, RPRX has a market cap of 19.8B. Regarding current trading prices, CTXR is priced at $0.88, while RPRX trades at $46.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CTXR currently has a P/E ratio of -0.36, whereas RPRX's P/E ratio is 25.90. In terms of profitability, CTXR's ROE is -0.53%, compared to RPRX's ROE of +0.12%. Regarding short-term risk, CTXR is more volatile compared to RPRX. This indicates potentially higher risk in terms of short-term price fluctuations for CTXR.Check RPRX's competition here
CTXR vs RVMD Comparison March 2026
CTXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CTXR stands at 9.8M. In comparison, RVMD has a market cap of 19.6B. Regarding current trading prices, CTXR is priced at $0.88, while RVMD trades at $99.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CTXR currently has a P/E ratio of -0.36, whereas RVMD's P/E ratio is -16.64. In terms of profitability, CTXR's ROE is -0.53%, compared to RVMD's ROE of -0.63%. Regarding short-term risk, CTXR is more volatile compared to RVMD. This indicates potentially higher risk in terms of short-term price fluctuations for CTXR.Check RVMD's competition here
CTXR vs DNA-WT Comparison March 2026
CTXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CTXR stands at 9.8M. In comparison, DNA-WT has a market cap of 18.7B. Regarding current trading prices, CTXR is priced at $0.88, while DNA-WT trades at $0.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CTXR currently has a P/E ratio of -0.36, whereas DNA-WT's P/E ratio is N/A. In terms of profitability, CTXR's ROE is -0.53%, compared to DNA-WT's ROE of -0.54%. Regarding short-term risk, CTXR is more volatile compared to DNA-WT. This indicates potentially higher risk in terms of short-term price fluctuations for CTXR.Check DNA-WT's competition here
CTXR vs INCY Comparison March 2026
CTXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CTXR stands at 9.8M. In comparison, INCY has a market cap of 18.5B. Regarding current trading prices, CTXR is priced at $0.88, while INCY trades at $93.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CTXR currently has a P/E ratio of -0.36, whereas INCY's P/E ratio is 14.51. In terms of profitability, CTXR's ROE is -0.53%, compared to INCY's ROE of +0.29%. Regarding short-term risk, CTXR is more volatile compared to INCY. This indicates potentially higher risk in terms of short-term price fluctuations for CTXR.Check INCY's competition here
CTXR vs GMAB Comparison March 2026
CTXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CTXR stands at 9.8M. In comparison, GMAB has a market cap of 16.4B. Regarding current trading prices, CTXR is priced at $0.88, while GMAB trades at $26.56.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CTXR currently has a P/E ratio of -0.36, whereas GMAB's P/E ratio is 17.25. In terms of profitability, CTXR's ROE is -0.53%, compared to GMAB's ROE of +0.11%. Regarding short-term risk, CTXR is more volatile compared to GMAB. This indicates potentially higher risk in terms of short-term price fluctuations for CTXR.Check GMAB's competition here
CTXR vs ASND Comparison March 2026
CTXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CTXR stands at 9.8M. In comparison, ASND has a market cap of 14.2B. Regarding current trading prices, CTXR is priced at $0.88, while ASND trades at $231.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CTXR currently has a P/E ratio of -0.36, whereas ASND's P/E ratio is -53.23. In terms of profitability, CTXR's ROE is -0.53%, compared to ASND's ROE of +1.28%. Regarding short-term risk, CTXR is more volatile compared to ASND. This indicates potentially higher risk in terms of short-term price fluctuations for CTXR.Check ASND's competition here
CTXR vs BBIO Comparison March 2026
CTXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CTXR stands at 9.8M. In comparison, BBIO has a market cap of 13.8B. Regarding current trading prices, CTXR is priced at $0.88, while BBIO trades at $71.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CTXR currently has a P/E ratio of -0.36, whereas BBIO's P/E ratio is -18.79. In terms of profitability, CTXR's ROE is -0.53%, compared to BBIO's ROE of +0.39%. Regarding short-term risk, CTXR is more volatile compared to BBIO. This indicates potentially higher risk in terms of short-term price fluctuations for CTXR.Check BBIO's competition here
CTXR vs KRTX Comparison March 2026
CTXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CTXR stands at 9.8M. In comparison, KRTX has a market cap of 12.6B. Regarding current trading prices, CTXR is priced at $0.88, while KRTX trades at $329.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CTXR currently has a P/E ratio of -0.36, whereas KRTX's P/E ratio is -28.09. In terms of profitability, CTXR's ROE is -0.53%, compared to KRTX's ROE of -0.36%. Regarding short-term risk, CTXR is more volatile compared to KRTX. This indicates potentially higher risk in terms of short-term price fluctuations for CTXR.Check KRTX's competition here
CTXR vs SMMT Comparison March 2026
CTXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CTXR stands at 9.8M. In comparison, SMMT has a market cap of 12B. Regarding current trading prices, CTXR is priced at $0.88, while SMMT trades at $16.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CTXR currently has a P/E ratio of -0.36, whereas SMMT's P/E ratio is -11.23. In terms of profitability, CTXR's ROE is -0.53%, compared to SMMT's ROE of -2.97%. Regarding short-term risk, CTXR is more volatile compared to SMMT. This indicates potentially higher risk in terms of short-term price fluctuations for CTXR.Check SMMT's competition here
CTXR vs IONS Comparison March 2026
CTXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CTXR stands at 9.8M. In comparison, IONS has a market cap of 11.9B. Regarding current trading prices, CTXR is priced at $0.88, while IONS trades at $72.34.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CTXR currently has a P/E ratio of -0.36, whereas IONS's P/E ratio is -30.39. In terms of profitability, CTXR's ROE is -0.53%, compared to IONS's ROE of -0.69%. Regarding short-term risk, CTXR is more volatile compared to IONS. This indicates potentially higher risk in terms of short-term price fluctuations for CTXR.Check IONS's competition here
CTXR vs RNAM Comparison March 2026
CTXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CTXR stands at 9.8M. In comparison, RNAM has a market cap of 11.3B. Regarding current trading prices, CTXR is priced at $0.88, while RNAM trades at $72.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CTXR currently has a P/E ratio of -0.36, whereas RNAM's P/E ratio is -17.39. In terms of profitability, CTXR's ROE is -0.53%, compared to RNAM's ROE of -0.45%. Regarding short-term risk, CTXR is more volatile compared to RNAM. This indicates potentially higher risk in terms of short-term price fluctuations for CTXR.Check RNAM's competition here
CTXR vs JAZZ Comparison March 2026
CTXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CTXR stands at 9.8M. In comparison, JAZZ has a market cap of 11.2B. Regarding current trading prices, CTXR is priced at $0.88, while JAZZ trades at $182.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CTXR currently has a P/E ratio of -0.36, whereas JAZZ's P/E ratio is -31.17. In terms of profitability, CTXR's ROE is -0.53%, compared to JAZZ's ROE of -0.09%. Regarding short-term risk, CTXR is more volatile compared to JAZZ. This indicates potentially higher risk in terms of short-term price fluctuations for CTXR.Check JAZZ's competition here
CTXR vs BMRN Comparison March 2026
CTXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CTXR stands at 9.8M. In comparison, BMRN has a market cap of 11B. Regarding current trading prices, CTXR is priced at $0.88, while BMRN trades at $57.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CTXR currently has a P/E ratio of -0.36, whereas BMRN's P/E ratio is 31.91. In terms of profitability, CTXR's ROE is -0.53%, compared to BMRN's ROE of +0.06%. Regarding short-term risk, CTXR is more volatile compared to BMRN. This indicates potentially higher risk in terms of short-term price fluctuations for CTXR.Check BMRN's competition here
CTXR vs EXEL Comparison March 2026
CTXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CTXR stands at 9.8M. In comparison, EXEL has a market cap of 11B. Regarding current trading prices, CTXR is priced at $0.88, while EXEL trades at $41.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CTXR currently has a P/E ratio of -0.36, whereas EXEL's P/E ratio is 14.77. In terms of profitability, CTXR's ROE is -0.53%, compared to EXEL's ROE of +0.37%. Regarding short-term risk, CTXR is more volatile compared to EXEL. This indicates potentially higher risk in terms of short-term price fluctuations for CTXR.Check EXEL's competition here
CTXR vs MDGL Comparison March 2026
CTXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CTXR stands at 9.8M. In comparison, MDGL has a market cap of 10B. Regarding current trading prices, CTXR is priced at $0.88, while MDGL trades at $440.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CTXR currently has a P/E ratio of -0.36, whereas MDGL's P/E ratio is -34.28. In terms of profitability, CTXR's ROE is -0.53%, compared to MDGL's ROE of -0.44%. Regarding short-term risk, CTXR is more volatile compared to MDGL. This indicates potentially higher risk in terms of short-term price fluctuations for CTXR.Check MDGL's competition here
CTXR vs RXDX Comparison March 2026
CTXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CTXR stands at 9.8M. In comparison, RXDX has a market cap of 9.6B. Regarding current trading prices, CTXR is priced at $0.88, while RXDX trades at $199.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CTXR currently has a P/E ratio of -0.36, whereas RXDX's P/E ratio is -56.47. In terms of profitability, CTXR's ROE is -0.53%, compared to RXDX's ROE of -0.31%. Regarding short-term risk, CTXR is more volatile compared to RXDX. This indicates potentially higher risk in terms of short-term price fluctuations for CTXR.Check RXDX's competition here
CTXR vs IMGN Comparison March 2026
CTXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CTXR stands at 9.8M. In comparison, IMGN has a market cap of 8.7B. Regarding current trading prices, CTXR is priced at $0.88, while IMGN trades at $31.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CTXR currently has a P/E ratio of -0.36, whereas IMGN's P/E ratio is -111.55. In terms of profitability, CTXR's ROE is -0.53%, compared to IMGN's ROE of -0.93%. Regarding short-term risk, CTXR is more volatile compared to IMGN. This indicates potentially higher risk in terms of short-term price fluctuations for CTXR.Check IMGN's competition here
CTXR vs IBRX Comparison March 2026
CTXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CTXR stands at 9.8M. In comparison, IBRX has a market cap of 8.4B. Regarding current trading prices, CTXR is priced at $0.88, while IBRX trades at $8.21.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CTXR currently has a P/E ratio of -0.36, whereas IBRX's P/E ratio is -21.61. In terms of profitability, CTXR's ROE is -0.53%, compared to IBRX's ROE of +0.64%. Regarding short-term risk, CTXR is more volatile compared to IBRX. This indicates potentially higher risk in terms of short-term price fluctuations for CTXR.Check IBRX's competition here
CTXR vs BPMC Comparison March 2026
CTXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CTXR stands at 9.8M. In comparison, BPMC has a market cap of 8.4B. Regarding current trading prices, CTXR is priced at $0.88, while BPMC trades at $129.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CTXR currently has a P/E ratio of -0.36, whereas BPMC's P/E ratio is -51.58. In terms of profitability, CTXR's ROE is -0.53%, compared to BPMC's ROE of -0.33%. Regarding short-term risk, CTXR is more volatile compared to BPMC. This indicates potentially higher risk in terms of short-term price fluctuations for CTXR.Check BPMC's competition here
CTXR vs CERE Comparison March 2026
CTXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CTXR stands at 9.8M. In comparison, CERE has a market cap of 8.2B. Regarding current trading prices, CTXR is priced at $0.88, while CERE trades at $44.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CTXR currently has a P/E ratio of -0.36, whereas CERE's P/E ratio is -16.47. In terms of profitability, CTXR's ROE is -0.53%, compared to CERE's ROE of -0.72%. Regarding short-term risk, CTXR is more volatile compared to CERE. This indicates potentially higher risk in terms of short-term price fluctuations for CTXR.Check CERE's competition here
CTXR vs AXSM Comparison March 2026
CTXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CTXR stands at 9.8M. In comparison, AXSM has a market cap of 8.1B. Regarding current trading prices, CTXR is priced at $0.88, while AXSM trades at $158.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CTXR currently has a P/E ratio of -0.36, whereas AXSM's P/E ratio is -43.00. In terms of profitability, CTXR's ROE is -0.53%, compared to AXSM's ROE of -2.54%. Regarding short-term risk, CTXR is more volatile compared to AXSM. This indicates potentially higher risk in terms of short-term price fluctuations for CTXR.Check AXSM's competition here
CTXR vs ABVX Comparison March 2026
CTXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CTXR stands at 9.8M. In comparison, ABVX has a market cap of 8B. Regarding current trading prices, CTXR is priced at $0.88, while ABVX trades at $122.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CTXR currently has a P/E ratio of -0.36, whereas ABVX's P/E ratio is -23.93. In terms of profitability, CTXR's ROE is -0.53%, compared to ABVX's ROE of +50.78%. Regarding short-term risk, CTXR is more volatile compared to ABVX. This indicates potentially higher risk in terms of short-term price fluctuations for CTXR.Check ABVX's competition here
CTXR vs ARWR Comparison March 2026
CTXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CTXR stands at 9.8M. In comparison, ARWR has a market cap of 8B. Regarding current trading prices, CTXR is priced at $0.88, while ARWR trades at $57.37.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CTXR currently has a P/E ratio of -0.36, whereas ARWR's P/E ratio is 35.86. In terms of profitability, CTXR's ROE is -0.53%, compared to ARWR's ROE of +0.36%. Regarding short-term risk, CTXR is more volatile compared to ARWR. This indicates potentially higher risk in terms of short-term price fluctuations for CTXR.Check ARWR's competition here
CTXR vs PCVX Comparison March 2026
CTXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CTXR stands at 9.8M. In comparison, PCVX has a market cap of 8B. Regarding current trading prices, CTXR is priced at $0.88, while PCVX trades at $55.62.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CTXR currently has a P/E ratio of -0.36, whereas PCVX's P/E ratio is -9.88. In terms of profitability, CTXR's ROE is -0.53%, compared to PCVX's ROE of -0.26%. Regarding short-term risk, CTXR is more volatile compared to PCVX. This indicates potentially higher risk in terms of short-term price fluctuations for CTXR.Check PCVX's competition here
CTXR vs TECH Comparison March 2026
CTXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CTXR stands at 9.8M. In comparison, TECH has a market cap of 7.6B. Regarding current trading prices, CTXR is priced at $0.88, while TECH trades at $48.81.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CTXR currently has a P/E ratio of -0.36, whereas TECH's P/E ratio is 92.09. In terms of profitability, CTXR's ROE is -0.53%, compared to TECH's ROE of +0.04%. Regarding short-term risk, CTXR is more volatile compared to TECH. This indicates potentially higher risk in terms of short-term price fluctuations for CTXR.Check TECH's competition here
CTXR vs HALO Comparison March 2026
CTXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CTXR stands at 9.8M. In comparison, HALO has a market cap of 7.6B. Regarding current trading prices, CTXR is priced at $0.88, while HALO trades at $64.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CTXR currently has a P/E ratio of -0.36, whereas HALO's P/E ratio is 25.11. In terms of profitability, CTXR's ROE is -0.53%, compared to HALO's ROE of +0.93%. Regarding short-term risk, CTXR is more volatile compared to HALO. This indicates potentially higher risk in terms of short-term price fluctuations for CTXR.Check HALO's competition here
CTXR vs CYTK Comparison March 2026
CTXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CTXR stands at 9.8M. In comparison, CYTK has a market cap of 7.5B. Regarding current trading prices, CTXR is priced at $0.88, while CYTK trades at $60.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CTXR currently has a P/E ratio of -0.36, whereas CYTK's P/E ratio is -9.30. In terms of profitability, CTXR's ROE is -0.53%, compared to CYTK's ROE of +1.73%. Regarding short-term risk, CTXR is more volatile compared to CYTK. This indicates potentially higher risk in terms of short-term price fluctuations for CTXR.Check CYTK's competition here
CTXR vs MTSR Comparison March 2026
CTXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CTXR stands at 9.8M. In comparison, MTSR has a market cap of 7.4B. Regarding current trading prices, CTXR is priced at $0.88, while MTSR trades at $70.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CTXR currently has a P/E ratio of -0.36, whereas MTSR's P/E ratio is -23.58. In terms of profitability, CTXR's ROE is -0.53%, compared to MTSR's ROE of -0.80%. Regarding short-term risk, CTXR is more volatile compared to MTSR. This indicates potentially higher risk in terms of short-term price fluctuations for CTXR.Check MTSR's competition here
CTXR vs KRYS Comparison March 2026
CTXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CTXR stands at 9.8M. In comparison, KRYS has a market cap of 7.3B. Regarding current trading prices, CTXR is priced at $0.88, while KRYS trades at $250.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CTXR currently has a P/E ratio of -0.36, whereas KRYS's P/E ratio is 36.52. In terms of profitability, CTXR's ROE is -0.53%, compared to KRYS's ROE of +0.19%. Regarding short-term risk, CTXR is more volatile compared to KRYS. This indicates potentially higher risk in terms of short-term price fluctuations for CTXR.Check KRYS's competition here
CTXR vs NUVL Comparison March 2026
CTXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CTXR stands at 9.8M. In comparison, NUVL has a market cap of 7.3B. Regarding current trading prices, CTXR is priced at $0.88, while NUVL trades at $99.53.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CTXR currently has a P/E ratio of -0.36, whereas NUVL's P/E ratio is -17.01. In terms of profitability, CTXR's ROE is -0.53%, compared to NUVL's ROE of -0.42%. Regarding short-term risk, CTXR is more volatile compared to NUVL. This indicates potentially higher risk in terms of short-term price fluctuations for CTXR.Check NUVL's competition here
CTXR vs MRUS Comparison March 2026
CTXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CTXR stands at 9.8M. In comparison, MRUS has a market cap of 6.8B. Regarding current trading prices, CTXR is priced at $0.88, while MRUS trades at $90.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CTXR currently has a P/E ratio of -0.36, whereas MRUS's P/E ratio is -17.05. In terms of profitability, CTXR's ROE is -0.53%, compared to MRUS's ROE of -0.51%. Regarding short-term risk, CTXR is more volatile compared to MRUS. This indicates potentially higher risk in terms of short-term price fluctuations for CTXR.Check MRUS's competition here
CTXR vs ACLX Comparison March 2026
CTXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CTXR stands at 9.8M. In comparison, ACLX has a market cap of 6.7B. Regarding current trading prices, CTXR is priced at $0.88, while ACLX trades at $114.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CTXR currently has a P/E ratio of -0.36, whereas ACLX's P/E ratio is -28.14. In terms of profitability, CTXR's ROE is -0.53%, compared to ACLX's ROE of -0.55%. Regarding short-term risk, CTXR is more volatile compared to ACLX. This indicates potentially higher risk in terms of short-term price fluctuations for CTXR.Check ACLX's competition here
CTXR vs RETA Comparison March 2026
CTXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CTXR stands at 9.8M. In comparison, RETA has a market cap of 6.6B. Regarding current trading prices, CTXR is priced at $0.88, while RETA trades at $172.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CTXR currently has a P/E ratio of -0.36, whereas RETA's P/E ratio is -66.29. In terms of profitability, CTXR's ROE is -0.53%, compared to RETA's ROE of +0.47%. Regarding short-term risk, CTXR is more volatile compared to RETA. This indicates potentially higher risk in terms of short-term price fluctuations for CTXR.Check RETA's competition here
CTXR vs BLTE Comparison March 2026
CTXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CTXR stands at 9.8M. In comparison, BLTE has a market cap of 6.5B. Regarding current trading prices, CTXR is priced at $0.88, while BLTE trades at $165.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CTXR currently has a P/E ratio of -0.36, whereas BLTE's P/E ratio is -71.59. In terms of profitability, CTXR's ROE is -0.53%, compared to BLTE's ROE of -0.43%. Regarding short-term risk, CTXR is more volatile compared to BLTE. This indicates potentially higher risk in terms of short-term price fluctuations for CTXR.Check BLTE's competition here
CTXR vs KYMR Comparison March 2026
CTXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CTXR stands at 9.8M. In comparison, KYMR has a market cap of 6.5B. Regarding current trading prices, CTXR is priced at $0.88, while KYMR trades at $79.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CTXR currently has a P/E ratio of -0.36, whereas KYMR's P/E ratio is -21.57. In terms of profitability, CTXR's ROE is -0.53%, compared to KYMR's ROE of -0.29%. Regarding short-term risk, CTXR is more volatile compared to KYMR. This indicates potentially higher risk in terms of short-term price fluctuations for CTXR.Check KYMR's competition here
CTXR vs PRAX Comparison March 2026
CTXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CTXR stands at 9.8M. In comparison, PRAX has a market cap of 6.4B. Regarding current trading prices, CTXR is priced at $0.88, while PRAX trades at $305.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CTXR currently has a P/E ratio of -0.36, whereas PRAX's P/E ratio is -22.61. In terms of profitability, CTXR's ROE is -0.53%, compared to PRAX's ROE of -0.59%. Regarding short-term risk, CTXR is more volatile compared to PRAX. This indicates potentially higher risk in terms of short-term price fluctuations for CTXR.Check PRAX's competition here
CTXR vs RYTM Comparison March 2026
CTXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CTXR stands at 9.8M. In comparison, RYTM has a market cap of 6.2B. Regarding current trading prices, CTXR is priced at $0.88, while RYTM trades at $90.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CTXR currently has a P/E ratio of -0.36, whereas RYTM's P/E ratio is -29.10. In terms of profitability, CTXR's ROE is -0.53%, compared to RYTM's ROE of -1.79%. Regarding short-term risk, CTXR is more volatile compared to RYTM. This indicates potentially higher risk in terms of short-term price fluctuations for CTXR.Check RYTM's competition here
CTXR vs PTGX Comparison March 2026
CTXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CTXR stands at 9.8M. In comparison, PTGX has a market cap of 6.2B. Regarding current trading prices, CTXR is priced at $0.88, while PTGX trades at $96.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CTXR currently has a P/E ratio of -0.36, whereas PTGX's P/E ratio is -47.20. In terms of profitability, CTXR's ROE is -0.53%, compared to PTGX's ROE of -0.20%. Regarding short-term risk, CTXR is more volatile compared to PTGX. This indicates potentially higher risk in terms of short-term price fluctuations for CTXR.Check PTGX's competition here
CTXR vs COGT Comparison March 2026
CTXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CTXR stands at 9.8M. In comparison, COGT has a market cap of 5.8B. Regarding current trading prices, CTXR is priced at $0.88, while COGT trades at $35.68.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CTXR currently has a P/E ratio of -0.36, whereas COGT's P/E ratio is -16.52. In terms of profitability, CTXR's ROE is -0.53%, compared to COGT's ROE of -1.00%. Regarding short-term risk, CTXR is more volatile compared to COGT. This indicates potentially higher risk in terms of short-term price fluctuations for CTXR.Check COGT's competition here
CTXR vs CDTX Comparison March 2026
CTXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CTXR stands at 9.8M. In comparison, CDTX has a market cap of 5.6B. Regarding current trading prices, CTXR is priced at $0.88, while CDTX trades at $221.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CTXR currently has a P/E ratio of -0.36, whereas CDTX's P/E ratio is -19.77. In terms of profitability, CTXR's ROE is -0.53%, compared to CDTX's ROE of -0.60%. Regarding short-term risk, CTXR is more volatile compared to CDTX. This indicates potentially higher risk in terms of short-term price fluctuations for CTXR.Check CDTX's competition here
CTXR vs CGON Comparison March 2026
CTXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CTXR stands at 9.8M. In comparison, CGON has a market cap of 5.6B. Regarding current trading prices, CTXR is priced at $0.88, while CGON trades at $65.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CTXR currently has a P/E ratio of -0.36, whereas CGON's P/E ratio is -31.68. In terms of profitability, CTXR's ROE is -0.53%, compared to CGON's ROE of -0.23%. Regarding short-term risk, CTXR is more volatile compared to CGON. This indicates potentially higher risk in terms of short-term price fluctuations for CTXR.Check CGON's competition here
CTXR vs PTCT Comparison March 2026
CTXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CTXR stands at 9.8M. In comparison, PTCT has a market cap of 5.5B. Regarding current trading prices, CTXR is priced at $0.88, while PTCT trades at $66.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CTXR currently has a P/E ratio of -0.36, whereas PTCT's P/E ratio is 7.78. In terms of profitability, CTXR's ROE is -0.53%, compared to PTCT's ROE of -3.62%. Regarding short-term risk, CTXR is more volatile compared to PTCT. This indicates potentially higher risk in terms of short-term price fluctuations for CTXR.Check PTCT's competition here
CTXR vs ABCM Comparison March 2026
CTXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CTXR stands at 9.8M. In comparison, ABCM has a market cap of 5.5B. Regarding current trading prices, CTXR is priced at $0.88, while ABCM trades at $23.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CTXR currently has a P/E ratio of -0.36, whereas ABCM's P/E ratio is 2399.00. In terms of profitability, CTXR's ROE is -0.53%, compared to ABCM's ROE of -0.01%. Regarding short-term risk, CTXR is more volatile compared to ABCM. This indicates potentially higher risk in terms of short-term price fluctuations for CTXR.Check ABCM's competition here
CTXR vs ISEE Comparison March 2026
CTXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CTXR stands at 9.8M. In comparison, ISEE has a market cap of 5.5B. Regarding current trading prices, CTXR is priced at $0.88, while ISEE trades at $39.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CTXR currently has a P/E ratio of -0.36, whereas ISEE's P/E ratio is -22.44. In terms of profitability, CTXR's ROE is -0.53%, compared to ISEE's ROE of -0.39%. Regarding short-term risk, CTXR is more volatile compared to ISEE. This indicates potentially higher risk in terms of short-term price fluctuations for CTXR.Check ISEE's competition here
CTXR vs CAI Comparison March 2026
CTXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CTXR stands at 9.8M. In comparison, CAI has a market cap of 5.4B. Regarding current trading prices, CTXR is priced at $0.88, while CAI trades at $19.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CTXR currently has a P/E ratio of -0.36, whereas CAI's P/E ratio is -5.92. In terms of profitability, CTXR's ROE is -0.53%, compared to CAI's ROE of +0.25%. Regarding short-term risk, CTXR is more volatile compared to CAI. This indicates potentially higher risk in terms of short-term price fluctuations for CTXR.Check CAI's competition here
CTXR vs FBIOX Comparison March 2026
CTXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CTXR stands at 9.8M. In comparison, FBIOX has a market cap of 5.4B. Regarding current trading prices, CTXR is priced at $0.88, while FBIOX trades at $24.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CTXR currently has a P/E ratio of -0.36, whereas FBIOX's P/E ratio is N/A. In terms of profitability, CTXR's ROE is -0.53%, compared to FBIOX's ROE of +0.00%. Regarding short-term risk, CTXR is more volatile compared to FBIOX. This indicates potentially higher risk in terms of short-term price fluctuations for CTXR.Check FBIOX's competition here
CTXR vs CELC Comparison March 2026
CTXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CTXR stands at 9.8M. In comparison, CELC has a market cap of 5.3B. Regarding current trading prices, CTXR is priced at $0.88, while CELC trades at $114.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CTXR currently has a P/E ratio of -0.36, whereas CELC's P/E ratio is -31.22. In terms of profitability, CTXR's ROE is -0.53%, compared to CELC's ROE of -1.79%. Regarding short-term risk, CTXR is more volatile compared to CELC. This indicates potentially higher risk in terms of short-term price fluctuations for CTXR.Check CELC's competition here
CTXR vs IMVT Comparison March 2026
CTXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CTXR stands at 9.8M. In comparison, IMVT has a market cap of 5.1B. Regarding current trading prices, CTXR is priced at $0.88, while IMVT trades at $25.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CTXR currently has a P/E ratio of -0.36, whereas IMVT's P/E ratio is -9.36. In terms of profitability, CTXR's ROE is -0.53%, compared to IMVT's ROE of -0.66%. Regarding short-term risk, CTXR is more volatile compared to IMVT. This indicates potentially higher risk in terms of short-term price fluctuations for CTXR.Check IMVT's competition here
CTXR vs ALKS Comparison March 2026
CTXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CTXR stands at 9.8M. In comparison, ALKS has a market cap of 4.7B. Regarding current trading prices, CTXR is priced at $0.88, while ALKS trades at $28.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CTXR currently has a P/E ratio of -0.36, whereas ALKS's P/E ratio is 19.58. In terms of profitability, CTXR's ROE is -0.53%, compared to ALKS's ROE of +0.14%. Regarding short-term risk, CTXR is more volatile compared to ALKS. This indicates potentially higher risk in terms of short-term price fluctuations for CTXR.Check ALKS's competition here
CTXR vs MIRM Comparison March 2026
CTXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CTXR stands at 9.8M. In comparison, MIRM has a market cap of 4.7B. Regarding current trading prices, CTXR is priced at $0.88, while MIRM trades at $92.64.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CTXR currently has a P/E ratio of -0.36, whereas MIRM's P/E ratio is -197.11. In terms of profitability, CTXR's ROE is -0.53%, compared to MIRM's ROE of -0.09%. Regarding short-term risk, CTXR is more volatile compared to MIRM. This indicates potentially higher risk in terms of short-term price fluctuations for CTXR.Check MIRM's competition here
CTXR vs CRSP Comparison March 2026
CTXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CTXR stands at 9.8M. In comparison, CRSP has a market cap of 4.6B. Regarding current trading prices, CTXR is priced at $0.88, while CRSP trades at $48.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CTXR currently has a P/E ratio of -0.36, whereas CRSP's P/E ratio is -7.48. In terms of profitability, CTXR's ROE is -0.53%, compared to CRSP's ROE of -0.32%. Regarding short-term risk, CTXR is more volatile compared to CRSP. This indicates potentially higher risk in terms of short-term price fluctuations for CTXR.Check CRSP's competition here
CTXR vs TGTX Comparison March 2026
CTXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CTXR stands at 9.8M. In comparison, TGTX has a market cap of 4.6B. Regarding current trading prices, CTXR is priced at $0.88, while TGTX trades at $28.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CTXR currently has a P/E ratio of -0.36, whereas TGTX's P/E ratio is 10.39. In terms of profitability, CTXR's ROE is -0.53%, compared to TGTX's ROE of +1.01%. Regarding short-term risk, CTXR is more volatile compared to TGTX. This indicates potentially higher risk in terms of short-term price fluctuations for CTXR.Check TGTX's competition here
CTXR vs XENE Comparison March 2026
CTXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CTXR stands at 9.8M. In comparison, XENE has a market cap of 4.5B. Regarding current trading prices, CTXR is priced at $0.88, while XENE trades at $54.66.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CTXR currently has a P/E ratio of -0.36, whereas XENE's P/E ratio is -12.54. In terms of profitability, CTXR's ROE is -0.53%, compared to XENE's ROE of -0.56%. Regarding short-term risk, CTXR is more volatile compared to XENE. This indicates potentially higher risk in terms of short-term price fluctuations for CTXR.Check XENE's competition here
CTXR vs FOLD Comparison March 2026
CTXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CTXR stands at 9.8M. In comparison, FOLD has a market cap of 4.5B. Regarding current trading prices, CTXR is priced at $0.88, while FOLD trades at $14.37.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CTXR currently has a P/E ratio of -0.36, whereas FOLD's P/E ratio is -159.67. In terms of profitability, CTXR's ROE is -0.53%, compared to FOLD's ROE of -0.12%. Regarding short-term risk, CTXR is more volatile compared to FOLD. This indicates potentially higher risk in terms of short-term price fluctuations for CTXR.Check FOLD's competition here
CTXR vs AKRO Comparison March 2026
CTXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CTXR stands at 9.8M. In comparison, AKRO has a market cap of 4.5B. Regarding current trading prices, CTXR is priced at $0.88, while AKRO trades at $54.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CTXR currently has a P/E ratio of -0.36, whereas AKRO's P/E ratio is -14.57. In terms of profitability, CTXR's ROE is -0.53%, compared to AKRO's ROE of -0.31%. Regarding short-term risk, CTXR is more volatile compared to AKRO. This indicates potentially higher risk in terms of short-term price fluctuations for CTXR.Check AKRO's competition here
CTXR vs ALPN Comparison March 2026
CTXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CTXR stands at 9.8M. In comparison, ALPN has a market cap of 4.5B. Regarding current trading prices, CTXR is priced at $0.88, while ALPN trades at $64.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CTXR currently has a P/E ratio of -0.36, whereas ALPN's P/E ratio is -101.52. In terms of profitability, CTXR's ROE is -0.53%, compared to ALPN's ROE of -0.13%. Regarding short-term risk, CTXR is more volatile compared to ALPN. This indicates potentially higher risk in terms of short-term price fluctuations for CTXR.Check ALPN's competition here
CTXR vs OPT Comparison March 2026
CTXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CTXR stands at 9.8M. In comparison, OPT has a market cap of 4.2B. Regarding current trading prices, CTXR is priced at $0.88, while OPT trades at $3.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CTXR currently has a P/E ratio of -0.36, whereas OPT's P/E ratio is -1.52. In terms of profitability, CTXR's ROE is -0.53%, compared to OPT's ROE of +0.88%. Regarding short-term risk, CTXR is more volatile compared to OPT. This indicates potentially higher risk in terms of short-term price fluctuations for CTXR.Check OPT's competition here
CTXR vs ERAS Comparison March 2026
CTXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CTXR stands at 9.8M. In comparison, ERAS has a market cap of 4.2B. Regarding current trading prices, CTXR is priced at $0.88, while ERAS trades at $13.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CTXR currently has a P/E ratio of -0.36, whereas ERAS's P/E ratio is -30.70. In terms of profitability, CTXR's ROE is -0.53%, compared to ERAS's ROE of -0.34%. Regarding short-term risk, CTXR is more volatile compared to ERAS. This indicates potentially higher risk in terms of short-term price fluctuations for CTXR.Check ERAS's competition here
CTXR vs VKTX Comparison March 2026
CTXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CTXR stands at 9.8M. In comparison, VKTX has a market cap of 4.2B. Regarding current trading prices, CTXR is priced at $0.88, while VKTX trades at $36.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CTXR currently has a P/E ratio of -0.36, whereas VKTX's P/E ratio is -11.29. In terms of profitability, CTXR's ROE is -0.53%, compared to VKTX's ROE of -0.48%. Regarding short-term risk, CTXR is more volatile compared to VKTX. This indicates potentially higher risk in terms of short-term price fluctuations for CTXR.Check VKTX's competition here
CTXR vs TERN Comparison March 2026
CTXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CTXR stands at 9.8M. In comparison, TERN has a market cap of 4.1B. Regarding current trading prices, CTXR is priced at $0.88, while TERN trades at $46.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CTXR currently has a P/E ratio of -0.36, whereas TERN's P/E ratio is -45.17. In terms of profitability, CTXR's ROE is -0.53%, compared to TERN's ROE of -0.30%. Regarding short-term risk, CTXR is more volatile compared to TERN. This indicates potentially higher risk in terms of short-term price fluctuations for CTXR.Check TERN's competition here
CTXR vs LGND Comparison March 2026
CTXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CTXR stands at 9.8M. In comparison, LGND has a market cap of 4.1B. Regarding current trading prices, CTXR is priced at $0.88, while LGND trades at $207.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CTXR currently has a P/E ratio of -0.36, whereas LGND's P/E ratio is 33.90. In terms of profitability, CTXR's ROE is -0.53%, compared to LGND's ROE of +0.14%. Regarding short-term risk, CTXR is more volatile compared to LGND. This indicates potentially higher risk in terms of short-term price fluctuations for CTXR.Check LGND's competition here
CTXR vs MRTX Comparison March 2026
CTXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CTXR stands at 9.8M. In comparison, MRTX has a market cap of 4.1B. Regarding current trading prices, CTXR is priced at $0.88, while MRTX trades at $58.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CTXR currently has a P/E ratio of -0.36, whereas MRTX's P/E ratio is -4.82. In terms of profitability, CTXR's ROE is -0.53%, compared to MRTX's ROE of -0.62%. Regarding short-term risk, CTXR is more volatile compared to MRTX. This indicates potentially higher risk in terms of short-term price fluctuations for CTXR.Check MRTX's competition here
CTXR vs SRRK Comparison March 2026
CTXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CTXR stands at 9.8M. In comparison, SRRK has a market cap of 4.1B. Regarding current trading prices, CTXR is priced at $0.88, while SRRK trades at $40.26.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CTXR currently has a P/E ratio of -0.36, whereas SRRK's P/E ratio is -12.24. In terms of profitability, CTXR's ROE is -0.53%, compared to SRRK's ROE of -1.46%. Regarding short-term risk, CTXR is more volatile compared to SRRK. This indicates potentially higher risk in terms of short-term price fluctuations for CTXR.Check SRRK's competition here
CTXR vs APGE Comparison March 2026
CTXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CTXR stands at 9.8M. In comparison, APGE has a market cap of 3.9B. Regarding current trading prices, CTXR is priced at $0.88, while APGE trades at $71.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CTXR currently has a P/E ratio of -0.36, whereas APGE's P/E ratio is -16.85. In terms of profitability, CTXR's ROE is -0.53%, compared to APGE's ROE of -0.37%. Regarding short-term risk, CTXR is more volatile compared to APGE. This indicates potentially higher risk in terms of short-term price fluctuations for CTXR.Check APGE's competition here
CTXR vs CRNX Comparison March 2026
CTXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CTXR stands at 9.8M. In comparison, CRNX has a market cap of 3.9B. Regarding current trading prices, CTXR is priced at $0.88, while CRNX trades at $37.28.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CTXR currently has a P/E ratio of -0.36, whereas CRNX's P/E ratio is -7.53. In terms of profitability, CTXR's ROE is -0.53%, compared to CRNX's ROE of -0.41%. Regarding short-term risk, CTXR is more volatile compared to CRNX. This indicates potentially higher risk in terms of short-term price fluctuations for CTXR.Check CRNX's competition here
CTXR vs CNTA Comparison March 2026
CTXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CTXR stands at 9.8M. In comparison, CNTA has a market cap of 3.8B. Regarding current trading prices, CTXR is priced at $0.88, while CNTA trades at $28.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CTXR currently has a P/E ratio of -0.36, whereas CNTA's P/E ratio is -14.97. In terms of profitability, CTXR's ROE is -0.53%, compared to CNTA's ROE of -0.68%. Regarding short-term risk, CTXR is more volatile compared to CNTA. This indicates potentially higher risk in terms of short-term price fluctuations for CTXR.Check CNTA's competition here
CTXR vs ADMA Comparison March 2026
CTXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CTXR stands at 9.8M. In comparison, ADMA has a market cap of 3.8B. Regarding current trading prices, CTXR is priced at $0.88, while ADMA trades at $15.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CTXR currently has a P/E ratio of -0.36, whereas ADMA's P/E ratio is 26.40. In terms of profitability, CTXR's ROE is -0.53%, compared to ADMA's ROE of +0.35%. Regarding short-term risk, CTXR is more volatile compared to ADMA. This indicates potentially higher risk in terms of short-term price fluctuations for CTXR.Check ADMA's competition here
CTXR vs RYZB Comparison March 2026
CTXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CTXR stands at 9.8M. In comparison, RYZB has a market cap of 3.8B. Regarding current trading prices, CTXR is priced at $0.88, while RYZB trades at $62.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CTXR currently has a P/E ratio of -0.36, whereas RYZB's P/E ratio is -57.86. In terms of profitability, CTXR's ROE is -0.53%, compared to RYZB's ROE of +0.83%. Regarding short-term risk, CTXR is more volatile compared to RYZB. This indicates potentially higher risk in terms of short-term price fluctuations for CTXR.Check RYZB's competition here
CTXR vs CBAY Comparison March 2026
CTXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CTXR stands at 9.8M. In comparison, CBAY has a market cap of 3.7B. Regarding current trading prices, CTXR is priced at $0.88, while CBAY trades at $32.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CTXR currently has a P/E ratio of -0.36, whereas CBAY's P/E ratio is -32.81. In terms of profitability, CTXR's ROE is -0.53%, compared to CBAY's ROE of -0.64%. Regarding short-term risk, CTXR is more volatile compared to CBAY. This indicates potentially higher risk in terms of short-term price fluctuations for CTXR.Check CBAY's competition here
CTXR vs ACAD Comparison March 2026
CTXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CTXR stands at 9.8M. In comparison, ACAD has a market cap of 3.6B. Regarding current trading prices, CTXR is priced at $0.88, while ACAD trades at $21.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CTXR currently has a P/E ratio of -0.36, whereas ACAD's P/E ratio is 9.30. In terms of profitability, CTXR's ROE is -0.53%, compared to ACAD's ROE of +0.42%. Regarding short-term risk, CTXR is more volatile compared to ACAD. This indicates potentially higher risk in terms of short-term price fluctuations for CTXR.Check ACAD's competition here
CTXR vs SWTX Comparison March 2026
CTXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CTXR stands at 9.8M. In comparison, SWTX has a market cap of 3.5B. Regarding current trading prices, CTXR is priced at $0.88, while SWTX trades at $46.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CTXR currently has a P/E ratio of -0.36, whereas SWTX's P/E ratio is -13.78. In terms of profitability, CTXR's ROE is -0.53%, compared to SWTX's ROE of -0.45%. Regarding short-term risk, CTXR is more volatile compared to SWTX. This indicates potentially higher risk in terms of short-term price fluctuations for CTXR.Check SWTX's competition here
CTXR vs KNSA Comparison March 2026
CTXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CTXR stands at 9.8M. In comparison, KNSA has a market cap of 3.5B. Regarding current trading prices, CTXR is priced at $0.88, while KNSA trades at $46.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CTXR currently has a P/E ratio of -0.36, whereas KNSA's P/E ratio is 62.00. In terms of profitability, CTXR's ROE is -0.53%, compared to KNSA's ROE of +0.11%. Regarding short-term risk, CTXR is more volatile compared to KNSA. This indicates potentially higher risk in terms of short-term price fluctuations for CTXR.Check KNSA's competition here
CTXR vs NAMS Comparison March 2026
CTXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CTXR stands at 9.8M. In comparison, NAMS has a market cap of 3.4B. Regarding current trading prices, CTXR is priced at $0.88, while NAMS trades at $29.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CTXR currently has a P/E ratio of -0.36, whereas NAMS's P/E ratio is -17.32. In terms of profitability, CTXR's ROE is -0.53%, compared to NAMS's ROE of -0.27%. Regarding short-term risk, CTXR is more volatile compared to NAMS. This indicates potentially higher risk in terms of short-term price fluctuations for CTXR.Check NAMS's competition here
CTXR vs CORT Comparison March 2026
CTXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CTXR stands at 9.8M. In comparison, CORT has a market cap of 3.4B. Regarding current trading prices, CTXR is priced at $0.88, while CORT trades at $32.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CTXR currently has a P/E ratio of -0.36, whereas CORT's P/E ratio is 39.24. In terms of profitability, CTXR's ROE is -0.53%, compared to CORT's ROE of +0.15%. Regarding short-term risk, CTXR is more volatile compared to CORT. This indicates potentially higher risk in terms of short-term price fluctuations for CTXR.Check CORT's competition here
CTXR vs DNLI Comparison March 2026
CTXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CTXR stands at 9.8M. In comparison, DNLI has a market cap of 3.3B. Regarding current trading prices, CTXR is priced at $0.88, while DNLI trades at $20.57.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CTXR currently has a P/E ratio of -0.36, whereas DNLI's P/E ratio is -6.93. In terms of profitability, CTXR's ROE is -0.53%, compared to DNLI's ROE of -0.50%. Regarding short-term risk, CTXR is more volatile compared to DNLI. This indicates potentially higher risk in terms of short-term price fluctuations for CTXR.Check DNLI's competition here
CTXR vs GPCR Comparison March 2026
CTXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CTXR stands at 9.8M. In comparison, GPCR has a market cap of 3.3B. Regarding current trading prices, CTXR is priced at $0.88, while GPCR trades at $56.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CTXR currently has a P/E ratio of -0.36, whereas GPCR's P/E ratio is -23.60. In terms of profitability, CTXR's ROE is -0.53%, compared to GPCR's ROE of -0.15%. Regarding short-term risk, CTXR is less volatile compared to GPCR. This indicates potentially lower risk in terms of short-term price fluctuations for CTXR.Check GPCR's competition here
CTXR vs EWTX Comparison March 2026
CTXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CTXR stands at 9.8M. In comparison, EWTX has a market cap of 3.2B. Regarding current trading prices, CTXR is priced at $0.88, while EWTX trades at $29.78.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CTXR currently has a P/E ratio of -0.36, whereas EWTX's P/E ratio is -18.27. In terms of profitability, CTXR's ROE is -0.53%, compared to EWTX's ROE of -0.32%. Regarding short-term risk, CTXR is more volatile compared to EWTX. This indicates potentially higher risk in terms of short-term price fluctuations for CTXR.Check EWTX's competition here
CTXR vs LQDA Comparison March 2026
CTXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CTXR stands at 9.8M. In comparison, LQDA has a market cap of 3.1B. Regarding current trading prices, CTXR is priced at $0.88, while LQDA trades at $35.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CTXR currently has a P/E ratio of -0.36, whereas LQDA's P/E ratio is -24.45. In terms of profitability, CTXR's ROE is -0.53%, compared to LQDA's ROE of -2.09%. Regarding short-term risk, CTXR is more volatile compared to LQDA. This indicates potentially higher risk in terms of short-term price fluctuations for CTXR.Check LQDA's competition here
CTXR vs IDYA Comparison March 2026
CTXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CTXR stands at 9.8M. In comparison, IDYA has a market cap of 3.1B. Regarding current trading prices, CTXR is priced at $0.88, while IDYA trades at $34.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CTXR currently has a P/E ratio of -0.36, whereas IDYA's P/E ratio is -27.18. In terms of profitability, CTXR's ROE is -0.53%, compared to IDYA's ROE of -0.11%. Regarding short-term risk, CTXR is more volatile compared to IDYA. This indicates potentially higher risk in terms of short-term price fluctuations for CTXR.Check IDYA's competition here
CTXR vs DYN Comparison March 2026
CTXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CTXR stands at 9.8M. In comparison, DYN has a market cap of 3B. Regarding current trading prices, CTXR is priced at $0.88, while DYN trades at $18.13.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CTXR currently has a P/E ratio of -0.36, whereas DYN's P/E ratio is -5.22. In terms of profitability, CTXR's ROE is -0.53%, compared to DYN's ROE of -0.61%. Regarding short-term risk, CTXR is more volatile compared to DYN. This indicates potentially higher risk in terms of short-term price fluctuations for CTXR.Check DYN's competition here
CTXR vs TARS Comparison March 2026
CTXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CTXR stands at 9.8M. In comparison, TARS has a market cap of 2.9B. Regarding current trading prices, CTXR is priced at $0.88, while TARS trades at $68.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CTXR currently has a P/E ratio of -0.36, whereas TARS's P/E ratio is -43.33. In terms of profitability, CTXR's ROE is -0.53%, compared to TARS's ROE of -0.20%. Regarding short-term risk, CTXR is more volatile compared to TARS. This indicates potentially higher risk in terms of short-term price fluctuations for CTXR.Check TARS's competition here
CTXR vs CPRX Comparison March 2026
CTXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CTXR stands at 9.8M. In comparison, CPRX has a market cap of 2.9B. Regarding current trading prices, CTXR is priced at $0.88, while CPRX trades at $23.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CTXR currently has a P/E ratio of -0.36, whereas CPRX's P/E ratio is 13.87. In terms of profitability, CTXR's ROE is -0.53%, compared to CPRX's ROE of +0.24%. Regarding short-term risk, CTXR is more volatile compared to CPRX. This indicates potentially higher risk in terms of short-term price fluctuations for CTXR.Check CPRX's competition here
CTXR vs MORF Comparison March 2026
CTXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CTXR stands at 9.8M. In comparison, MORF has a market cap of 2.9B. Regarding current trading prices, CTXR is priced at $0.88, while MORF trades at $56.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CTXR currently has a P/E ratio of -0.36, whereas MORF's P/E ratio is -14.88. In terms of profitability, CTXR's ROE is -0.53%, compared to MORF's ROE of -0.29%. Regarding short-term risk, CTXR is more volatile compared to MORF. This indicates potentially higher risk in terms of short-term price fluctuations for CTXR.Check MORF's competition here
CTXR vs VERA Comparison March 2026
CTXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CTXR stands at 9.8M. In comparison, VERA has a market cap of 2.9B. Regarding current trading prices, CTXR is priced at $0.88, while VERA trades at $40.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CTXR currently has a P/E ratio of -0.36, whereas VERA's P/E ratio is -8.59. In terms of profitability, CTXR's ROE is -0.53%, compared to VERA's ROE of -0.60%. Regarding short-term risk, CTXR is more volatile compared to VERA. This indicates potentially higher risk in terms of short-term price fluctuations for CTXR.Check VERA's competition here
CTXR vs MOR Comparison March 2026
CTXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CTXR stands at 9.8M. In comparison, MOR has a market cap of 2.9B. Regarding current trading prices, CTXR is priced at $0.88, while MOR trades at $18.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CTXR currently has a P/E ratio of -0.36, whereas MOR's P/E ratio is -12.64. In terms of profitability, CTXR's ROE is -0.53%, compared to MOR's ROE of -1.84%. Regarding short-term risk, CTXR is more volatile compared to MOR. This indicates potentially higher risk in terms of short-term price fluctuations for CTXR.Check MOR's competition here
CTXR vs DNTH Comparison March 2026
CTXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CTXR stands at 9.8M. In comparison, DNTH has a market cap of 2.8B. Regarding current trading prices, CTXR is priced at $0.88, while DNTH trades at $78.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CTXR currently has a P/E ratio of -0.36, whereas DNTH's P/E ratio is -22.29. In terms of profitability, CTXR's ROE is -0.53%, compared to DNTH's ROE of +0.00%. Regarding short-term risk, CTXR is more volatile compared to DNTH. This indicates potentially higher risk in terms of short-term price fluctuations for CTXR.Check DNTH's competition here
CTXR vs ARQT Comparison March 2026
CTXR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CTXR stands at 9.8M. In comparison, ARQT has a market cap of 2.8B. Regarding current trading prices, CTXR is priced at $0.88, while ARQT trades at $22.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CTXR currently has a P/E ratio of -0.36, whereas ARQT's P/E ratio is -175.08. In terms of profitability, CTXR's ROE is -0.53%, compared to ARQT's ROE of -0.10%. Regarding short-term risk, CTXR is more volatile compared to ARQT. This indicates potentially higher risk in terms of short-term price fluctuations for CTXR.Check ARQT's competition here